OncoZenge investor relations material

OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. Its products include Palonosetron Fertiginject, an antiemetic product developed and launched in the Nordics; and Yserenate, a pharmaceutical preparation that is used for the treatment of hyperammonemia in patients with N-acetylglutamate synthase deficiency, as well as for the treatment of hypophosphatemia in patients with chronic kidney disease. The company was founded in 2020 and is headquartered in Bromma, Sweden.